How will clinical trials be impacted by the UK’s decision to leave the European Union?
The United Kingdom’s decision to leave the European Union (EU) will present significant implications to the pharmaceutical industry. Clinical trial sponsors and associated partners should be prepared for a variety of scenarios arising from Brexit which could impact on the manufacturing, licensing and distribution of health products between Ireland and the UK.
Clinical trial sponsors will have to navigate different sets of guidelines, which could potentially increase study times and inflate costs.
Firstly, the manner in which clinical trials are conducted in the EU will undergo a major change when the Clinical Trial Regulation comes into application. The Regulation (EU No 536/2014) harmonises the assessment and supervision processes for clinical trials throughout the EU, via a centralised portal, and will come into force in 2020. Since this will happen after the UK leaves the EU, the UK will not be in line with EU regulations and UK’s future alignment will be subject to negotiations with the EU. In the case of No-Deal Brexit scenario regarding medicinal products between the EU and the UK, the following issues concerning clinical trials with medicinal products must be observed: